H-CYTE, INC.: management transactions · United States · SEC (Form 4)

About H-CYTE, INC.

H-CYTE, INC. is a United States-listed healthcare company with a micro-cap profile and a business model that remains in transition. Historically known as Medovex Corp, the company was renamed H-CYTE, Inc. and is now presented in SEC filings as a hybrid biopharmaceutical business focused on chronic respiratory and pulmonary disorders. SEC documents place its principal operating location in Tampa, Florida, United States, while the company’s clinic-related footprint has been associated with Lung Health Institute, later rebranded as Centers for Respiratory Health. The company’s strategy is built around two complementary operating segments. First, its autologous infusion therapy business provides patient-specific treatments aimed at chronic lung conditions. Second, its biologics development division is intended to create and develop new therapies for underserved disease states. This combination gives H-CYTE a dual profile: part clinical services provider, part early-stage biotech developer. For investors, that means the equity should be viewed as a high-risk, high-uncertainty healthcare story rather than a mature operating platform. From a competitive standpoint, H-CYTE operates in a crowded and highly regulated market where scale, capital access, reimbursement, and clinical validation matter enormously. It does not appear to compete on broad commercial breadth; instead, its positioning is based on specialization in respiratory care and on the possibility that its biologics pipeline could generate differentiated value over time. Relative to larger U.S. healthcare and biotech peers, H-CYTE’s strategic edge is narrower and more speculative, but potentially more asymmetric if execution improves. Recent corporate developments highlighted in SEC filings include the company’s continued restructuring around respiratory health, the permanent closure of some clinic locations after the COVID period, and multiple financing transactions involving secured convertible notes in 2021. Those capital events underscore the company’s dependence on external funding and the potential for share dilution, which are important considerations for equity investors monitoring Form 4 insider activity and broader ownership dynamics. The company’s website also indicates that its online investor resources are maintained separately and updated through its investor-relations portal. In short, H-CYTE, INC. should be framed as a United States healthcare microcap, listed on the NYSE/NASDAQ ecosystem in the broad sense of U.S. public markets, with a business centered on respiratory care services and biologics development. Its investment case depends on clinical execution, funding discipline, and the ability to convert a niche healthcare thesis into sustainable commercial traction.